Nava Sara, Lisini Daniela, Frigerio Simona, Pogliani Simona, Pellegatta Serena, Gatti Laura, Finocchiaro Gaetano, Bersano Anna, Parati Eugenio Agostino
Cell Therapy Production Unit-UPTC and Cerebrovascular Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milan, Italy.
Unit of Molecular Neuro-Oncology, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milan, Italy.
Pharmaceutics. 2020 Mar 2;12(3):215. doi: 10.3390/pharmaceutics12030215.
Dendritic cells (DC) are the most potent antigen-presenting cells, strongly inducers of T cell-mediated immune responses and, as such, broadly used as vaccine adjuvant in experimental clinical settings. DC are widely generated from human monocytes following in vitro protocols which require 5-7 days of differentiation with GM-CSF and IL-4 followed by 2-3 days of activation/maturation. In attempts to shorten the vaccine's production, Fast-DC protocols have been developed. Here we reported a Fast-DC method in compliance with good manufacturing practices for the production of autologous mature dendritic cells loaded with antigens derived from whole tumor lysate, suitable for the immunotherapy in glioblastoma patients. The feasibility of generating Fast-DC pulsed with whole tumor lysate was assessed using a series of small-scale cultures performed in parallel with clinical grade large scale standard method preparations. Our results demonstrate that this Fast protocol is effective only in the presence of PGE in the maturation cocktail to guarantee that Fast-DC cells exhibit a mature phenotype and fulfill all requirements for in vivo use in immunotherapy approaches. Fast-DC generated following this protocol were equally potent to standard DC in inducing Ag-specific T cell proliferation in vitro. Generation of Fast-DC not only reduces labor, cost, and time required for in vitro clinical grade DC development, but can also minimizes inter-preparations variability and the risk of contamination.
树突状细胞(DC)是最有效的抗原呈递细胞,是T细胞介导的免疫反应的强力诱导剂,因此在实验临床环境中广泛用作疫苗佐剂。DC可通过体外方案从人单核细胞大量生成,该方案需要用GM-CSF和IL-4进行5-7天的分化,然后进行2-3天的激活/成熟。为了缩短疫苗生产时间,已开发出快速DC方案。在此,我们报告了一种符合良好生产规范的快速DC方法,用于生产负载源自全肿瘤裂解物的抗原的自体成熟树突状细胞,适用于胶质母细胞瘤患者的免疫治疗。使用与临床级大规模标准方法制备平行进行的一系列小规模培养,评估了用全肿瘤裂解物脉冲产生快速DC的可行性。我们的结果表明,该快速方案仅在成熟混合物中存在PGE的情况下才有效,以确保快速DC细胞表现出成熟的表型,并满足免疫治疗方法体内使用的所有要求。按照该方案产生的快速DC在体外诱导抗原特异性T细胞增殖方面与标准DC同样有效。快速DC的产生不仅减少了体外临床级DC开发所需的劳动力、成本和时间,还可以最大限度地减少制剂间的变异性和污染风险。